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Rapport de synthèse 
Hypoglycémies nocturnes chez les patients diabétiques de type 1 : que pouvons-nous 
apprendre de la mesure de la glycémie en continu ? 
But : les hypoglycémies nocturnes sont une complication majeure du traitement des patients 
diabétiques de type 1; des autocontrôles de la glycémie capillaire sont donc recommandés 
pour les détecter. Cependant, la majorité des hypoglycémies nocturnes ne sont pas 
décelées par un autocontrôle glycémique durant la nuit. La mesure de la glycémie en continu 
(CGMS) est une alternative intéressante. Les buts de cette étude rétrospective étaient 
d'évaluer la véritable incidence des hypoglycémies nocturnes chez des patients diabétiques 
de type 1, la meilleure période pour effectuer un autocontrôle permettant de prédire une 
hypoglycémie nocturne, la relation entre les hyperglycémies matinales et les hypoglycémies 
nocturnes (phénomène de Somogyi) ainsi que l'utilité du CGMS pour réduire les 
hypoglycémies nocturnes. 
Méthode : quatre-vingt-huit patients diabétiques de type 1 qui avaient bénéficié d'un CGMS 
ont été inclus. Les indications au CGMS, les hypoglycémies nocturnes et diurnes ainsi que la 
corrélation entre les hypoglycémies nocturnes et les hyperglycémies matinales durant le 
CGMS ont été enregistrées. L'efficacité du CGMS pour réduire les hypoglycémies nocturnes 
a été évaluée six à neuf mois après. 
Résultats: la prévalence des hypoglycémies nocturnes était de 67% (32% non suspectées). 
La sensibilité d'une hypoglycémie à prédire une hypoglycémie nocturne était de 37% (OR = 
2,37, P = 0,001) lorsqu'elle survient au coucher (22-24 h) et de 43% lorsqu'elle survient à 3 h 
(OR= 4,60, P < 0,001 ). Les hypoglycémies nocturnes n'étaient pas associées à des 
hyperglycémies matinales, mais à des hypoglycémies matinales (OR = 3.95, P < 0.001 ). Six 
à neuf mois après le CGMS, les suspicions cliniques d'hypoglycémies nocturnes ont diminué 
de 60% à 14% (P < 0.001 ). 
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Aim. - In type 1 diabetic patients (TIDM), nocturnal hypoglycaemias (NH) are a serious complication ofTIDM treatment; self-monitoring of 
blood glucose (SMBG) is recommended to detect !hem. However, the majority of NH remains undetected on an occasional SMBG done during 
the night. An alternative sh·ategy is the Continuous glucose monitoring (CGMS), which retrospectively shows the glycaemic profile. The aims of 
this retrospective study were to evaluate the !rue incidence of NH in TIDM, the best SMBG time to predict NH, the relationship between 
morning hyperglycaemia and NH (Somogyi phenomenon) and the utility of CGMS to reduce NH. 
Methods. - Eighty-eight TIDM who underwent a CGMS exam were included. Indications for CGMS evaluation, hypoglycaemias and corre-
lation with morning hyperglycaemias were recorded. The efficiency of CGMS to reduce the suspected NH was evaluated after 6-9 months. 
Results. - The prevalence ofNH was 67% (32% of them unsuspected). A measured hypoglycaemia at bedtime (22-24 h) had a sensitivity of 
37% to detect NH (OR= 2.37, P = 0.001), while a single measure :<:: 4 mmol/l at 3-hour had a sensitivity of 43% (OR= 4.60, P < 0.001). NH 
were not associated with morning hyperglycaemias but with morning hypoglycaemias (OR= 3.95, P < 0.001). After 6-9 months, suspicions of 
NH decreased from 60 to 14% (P < 0.001). 
Conclusion. - NH were highly prevalent and often undetected. SMBG at bedtime, which detected hypoglycaemia had sensitivity almost equal 
to that of 3-hour and should be preferred because it is easier to perform. Somogyi phenomenon was not observed. CGMS is useful to reduce the 
risk ofNH in 75% of patients. 
© 2007 Elsevier Masson SAS. AU rights reserved. 
Résumé 
Hypoglycémies nocturnes chez les patients diabétiques de type 1 : que pouvons-nous apprendre de la mesure de la glycémie en continu? 
But. - Les hypoglycémies nocturnes sont une complication majeure du traitement des patients diabétiques de type 1; des autocontrôles de la 
glycémie capillaire sont donc recommandés pour les détecter. Cependant, la majorité des hypoglycémies nocturnes ne sont pas décelées par un 
autocontrôle glycémique durant la nuit. La mesure de la glycémie en continu (CGMS) est une alternative intéressante. Les buts de cette étude 
rétrospective étaient d'évaluer la véritable incidence des hypoglycémies nocturnes chez des patients diabétiques de type 1, la meilleure période 
pour effectuer un autocontrôle qui permet de prédire une hypoglycémie nocturne, la relation entre les hyperglycémies matinales et les hypogly-
cémies nocturnes (phénomène de Somogyi) ainsi que l'utilité du CGMS pour réduire les hypoglycémies nocturnes. 
Méthode. - Quatre-vingt-huit patients diabétiques de type 1 qui avaient bénéficié d'un CGMS ont été inclus. Les indications au CGMS, les 
hypoglycémies nocturnes et diurnes ainsi que la corrélation entre les hypoglycémies nocturnes et les hyperglycémies matinales durant le CGMS 
ont été enregish·ées. L'efficacité du CGMS pour réduire les hypoglycémies nocturnes a été évaluée six à neuf mois après. 
Résultats. - La prévalence des hypoglycémies nocturnes était de 67 % (32 % non suspectées). La sensibilité d'une hypoglycémie à prédire une 
hypoglycémie nocturne était de 37 % (OR= 2,37, P = 0,001) lorsqu'elle survient au coucher (22-24 h) et de 43 % lorsqu'elle survient à 3 h 
(OR= 4,60, P < 0,001). Les hypoglycémies nocturnes n'étaient pas associées à des hyperglycémies matinales, mais à des hypoglycémies mati-
nales (OR= 3,95, P < 0,001). Six à neuf mois après le CGMS, les suspicions cliniques d'hypoglycémie nocturne ont diminué de 60 à 14 % 
(P<0,001). 
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Conclusions. - Les hypoglycémies nocturnes ont une prévalence élevée et ne sont souvent pas détectées par les autocontrôles. La détection 
d'une hypoglycémie au coucher a une sensibilité équivalente à celle de 3 h pour prédire une hypoglycémie nocturne. Par conséquent, un auto-
contrôle au coucher, moins contraignant qu'à 3H, peut donc être une stratégie conseillée. Le phénomène de Somogyi n'a pas été observé. Le 
CGMS est utile pour réduire les hypoglycémies nocturnes suspectées chez 75 % des patients. 
© 2007 Elsevier Masson SAS. Ali rights reserved. 
Keywords: Continuons glucose monitoring system; Noctumal hypoglycaemia; Self-monitoring of blood glucose; Type 1 diabetes mellitus 
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1. Introduction 
The DCCT study has shown that intensive insulin therapy 
has a major effect on the prevention of micro-vascular compli-
cations in type 1 diabetic patients (TlDM) [ 1]. This study has 
also shown that intensive glycaemic control induces three 
times more severe hypoglycaemic episodes. Other studies sug-
gested a high prevalence ofnoctumal hypoglycaemia in TlDM 
[2-4,28]. These hypoglycaemic episodes often go unnoticed 
and may have serious consequences on cognitive functions 
[5,6]. Moreover, these patients are at high risk for major hypo-
glycaemia [6). It is therefore important to evaluate the glucose 
profile during the night. Classically, noctumal hypoglycaemia 
evaluation is performed by self-monitoring of blood glucose 
(SMBG) at a precise moment, arbitrarily set at 03 h. Thus, 
patients have to wake up to perform this test. Furthermore, 
when a physician is dealing with marked hyperglycaemia in 
the moming, he has to investigate if it is a rebound phenom-
enon as described by Somogyi [7], a dawn phenomenon caused 
by an increase of counterregulatory hormones, an omission of 
insulin or a hearty meal the previous evening [8]. Somogyi 
reported in 1959 that undetected noctumal hypoglycaemia 
could cause rebound moming hyperglycaemia secondary to 
an increase in glucose production due to activation of glucose 
regulatory systems [7]. This phenomenon has been widely 
accepted by clinicians to explain moming hyperglycaemias; 
however, it is controversial and some studies rejected this 
hypothesis [8 1 O]. 
Since the development of SMBG, it seems obvious that 
daily glucose measurements, at strategically chosen moments, 
help to individually adapt the insulin regimen. The objective is 
to reach the best possible glycaemic control with the lowest 
rate of hypoglycaemic events. If SMBG are done regularly, 
they allow to significantly reducing glycosylated hemoglobin 
(HbA10) [11,12]. Glucosensor®, a continuous glucose monitor-
ing system (CGMS), which measures interstitial glucose level 
by an abdominal subcutaneous sensor, shows its usefulness by 
giving complete glycaemic profiles of patients. It allows eva-
luation or glycaemic variations between SMBG measures and 
is therefore particularly useful to evaluate postprandial excur-
sions [2,4,13], noctumal and diurnal hypoglycaemias [14-16]. 
It brings educative information to the patient, who is con-
fronted with his continuous glycaemic profile [17,18] and can 
see effects of food intake, physical activity, inappropriate insu-
lin corrections and importance of SMBG [17]. The CGMS is 
not routinely used because of high cost, discomfort for the 
patient and problems of availability in some centers. A great 
limitation to CGMS is its accuracy, especially during hypogly-
caemic episodes. Clarke's study suggests that the CGMS 
misses the nadir of hypoglycaemia and underevaluates the 
duration of hypoglycaemia [19]. Guerci et al. obse1ved that 
the data of the CGMS were less accurate compared to capillary 
measurement by SMBG to evaluate the real glycaemia [20]. 
Then we considered the CGMS principally as an educational 
tool for our patients and physicians and not as a gold standard. 
In this study, the aim was to identify information from the 
CGMS applicable to patients who cannot routinely benefit 
from this technique. We have collected the indications for 
CGMS use, and have evaluated the real prevalence of noctur-
nal hypoglycaemia (NH) in Tl DM, correlateci to the frequency 
of clinical suspicion of NH. We tested the potential efficiency 
of SMBG at bedtime (22-24 h) and at 03 h in predicting the 
risk of NH. We compared the population of patients who had 
NH during the CGMS with patients who had not, to determine 
predicting factors ofNH. We have also studied the relationship 
between NH and fasting glycaemia to understand if moming 
hyperglycaemia was related to NH as described by Somogyi 
[7], or with the persistence of hyperglycaemia during the 
night [8]. Finally, we assessed the potential glycaemic and 
metabolic improvement and the reduction ofNH 6 to 9 months 
after CGMS. 
2. Methods 
2.1. Subjects 
In this retrospective study, CGMS data from TlDM of the 
clinical outpatient consultation of the University Hospital in 
Lausanne, Switzerland, were collected from August 2001 to 
December 2003 and then analyzed. Only TlDM who under-
went a CGMS exam were included. Medical records of these 
patients were reviewed: age, sex, diabetes duration, antidiabetic 
treatment, diabetes complications, smoking, sedentarity, body 
mass index (kg/m2), SMBG values of the days before CGMS, 
HbA1 0 before CGMS, clinical suspicion of noctumal hypogly-
caemia, CGMS indications and CGMS values of the entire 
record were evaluated. Then SMBG values, HbA10 (normal 
values 4.9-6.5%) and suspicion of noctumal hypoglycaemias 
6-9 months after CGMS were recorded. 
2.2. Continuous glucose monitoring of blood glucose (CGMS) 
Patients came to the diabetology outpatient clinic for the 
installation of CGMS (Medtronic Minimed, Sy1mar, Califomia, 
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USA). Installation and operation of CGMS are described else-
where [21]. Patients were asked to behave as usual and to 
report in a diary food intake and doses of insulin, physical 
activity and symptoms ofhypoglycaemia. Those are classically 
described as: abnormal sweat, tremor, hunger, pallor, head-
ache, irritability and cognitive alteration; noctumal hypogly-
caemia is recognized by abnormal sweat, disturbed sleep and 
nightmares [6]. Patients were instrncted to perform four times 
daily SMBG (with their own device for glucose control) to 
calibrate the CGMS. Each sensor was installed for 72 hours. 
After removal of the sensor, data were analyzed (Medtronic 
Minimed CGMS Software, version 1.7 A). A graphical report 
of glycaemic profile was printed and discussed with the 
patients. Comments were reported in a medical file. Then, pre-
cise objectives were fixed in order to improve the metabolic 
profile of the patient. These objectives were based on the indi-
cations for Glucosensor and on other problems revealed by this 
test. 
3. Data analysis 
W e used only the CGMS records that were not interrnpted. 
W e defined early moming as the period between 06 h and 
10 h, bedtime as the period between 22 h and 24 h and the 
night as the period between 24 h and 06 h. We studied for 
each period the duration (minutes) of euglycaemia, hypo-
glycaemia and hyperglycaemia. Hypoglycaemia was defined 
as a glucose level :::: 4 mmol/l and hyperglycaemia 2: 8 mmol/L 
A hypoglycaemic event was defined as a glucose level 
:S 4 mmol/l during 2: 15 minutes, a hyperglycaemic event as a 
glucose level 2: 8 mmol/l during 2: 30 minutes. Barly moming, 
bedtime and noctumal hypoglycaemia were defined by 
2: 1 hypoglycaemic event between 06-10 h, 22-24 h and 
24-06 h, respectively. To evaluate the potential usefulness of 
the SMBG at 03 h, we chose a single CGMS measure at 03 h 
and coffelated it with the presence ofNH. We also studied the 
correlation between bedtime hypoglycaemia and NH and early 
moming hyperglycaemia and between NH and early moming 
hypoglycaemia. 
Associations between the lev el of blood glucose at 03 h and 
the presence ofNH, between the presence ofhypoglycaemia at 
bedtime and NH and finally between the glycaemia on the 
moming and the presence of NH, were studied for each night 
separately (lst, 2nd and 3rd). The results were given for the 
two nights with the highest correlation (higher odd ratio). 
3.1. Statistical analysis 
Continuous variables, normally distributed, were expressed 
in means with standard deviation and the Student's t-test was 
used for comparisons. Non-normally distributed continuous 
variables were expressed as median, with 1 Oth-90th percentiles 
and the Mann-Whitney Utest was used for comparisons. Cate-
gorical variables were expressed in frequency and differences 
were based on the chi-square test. All statistical analyses were 
performed using JMP 5.0 (SAS Institute, Cary, USA) and a P 
value :::: 0.05 was considered statistically significant. 
4. Results 
4.1. Indications for CGMS 
The two most frequent indications for CGMS were diabetes 
imbalance (56%) and suspicion of noctumal hypoglycaemia 
(NH) (27%). After study of ail preliminary data, NH were sus-
pected in 60% of the patients. Other indications were hypergly-
caemia, daytime hypoglycaemia, patient's educative interest, 
glycaemia's evaluation before the initiation of pump therapy 
and suspicion of Somogyi phenomenon. 
4.2. Population description 
The clinical characteristics of the study population are 
shown in Table 1. Eighty-eight TlDM were included, aged 
39 ± 12 years. Fifty-six percent were males (N = 49) and med-
ian diabetes duration was 13 years (5-35). Median HbA10 was 
8.4% (6.8-9.9). 
4.3. CGMS 
The global evaluation of the CGMS is shown in Fig. l. 
Conceming NH, 67% of the patients (N = 59) had at least 
one episode during the recording. In the group of patients 
who had NH during CGMS, 32% were not clinically suspected 
and were detected by CGMS only (OR= 1.39, P = 0.039). The 
prevalence of hypoglycaemia during the day was already high: 
82% of patients had at least one episode of diurnal hypogly-
caemia during the recording. The median coefficient correla-
tion R of the CGMS recordings was 0.91 (0.67-0.99). 
4.4. Capacity of hypothetical SMBG to detect NH 
In the 2nd and 3rd nights, there was a strong correlation 
between NH and bedtime hypoglycaemia (OR= 2.37, 
P = 0.001) and between a single CGMS measure::; 4 mmol/l 
at 03 h and NH (OR= 4.60, P < 0.001). The sensitivity of an 
Table 1 
Population characteristic~ 
N 
Male gender 
Age (years)" 
Diabetes duration (years ):j: 
CmTent smoking 
BMI (kg/m2):j: 
HbA1c (%):j: 
Retinopathy 
Sensitive neuropathy 
Nephropathy 
Coronary art~ry disease 
Lower limb arteriopathy 
Insu/in treatment 
Basal bolus 
Insulin pump 
Mixed insulin 
:j:Median (pl0-p90). 
• Mean±S.D. 
88 
56% 
39± 12 
13 (5-35) 
27% 
22.9 (19.7-28.8) 
8.4 (6.8-9.9) 
19% 
34% 
16% 
5% 
4% 
NPH +Fast-acting analog 34% 
Glargine +Fast-acting analog 22% 
NPH +Normal 7% 
30% 
7% 
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m Glycaemlc prollles durlng 24h (ô) lime spènl ln dlflerent glycaemlc 
:._~; of CGMS recordJngs: percentage - categorles durlng 24h of the CGMS 
of patients in several levais 
of glycaemla 
11% 
61% 
~ Hyperglycaernia dorlng the 24H 
D Alternance of episodes of hyper 
and hypoglycaemla 
D Hypoglycaemia 
llllll Other profilas of grycaemia 
41% 49% 
li Hypergrycaemla ( > 8mmol/I) 
O Hypoglycaernia ( < 4mrnoVI) 
O other glycaemlc profiles 
Fig. 1. Global evaluation of the CGMS. 
episode of hypoglycaemia at bedtime to detect NH was 37% 
(negative predictive value NPV 74%), while a single CGMS 
measure ::; 4 at 03 h had a sensitivity to detect NH of 43% 
(NPV 78%), Sensitivity and NPV not significantly different 
(Table 2). 
4.5. Univaried predictors of NH 
Table 3 compares data of patients with and without NH dur-
ing CGMS measures. In patients with NH, HbA1c was signifi-
Table 2 
Detection of noctumal hypoglycaemias (24--06 h) 
Hypoglycaemia 22-24 h 
Sensitivity 37% 
Specificity 89% 
VPP 62% 
VPN 74% 
OR 2.37 
p <0.01 
Table 3 
Hypoglycaemia 3 h 
43% 
100% 
100% 
78% 
4.6 
<0.01 
Univaried predictors of noctumal hypoglycaemias (NH) 
--------·------···-····----------------------------·-·--·· ----
N=88 
Male gender 
Age (years )" 
Diabetes duration (years )t 
Cuffent smoking 
BMI (kg/m2)t 
HbA1c (%):j: 
Microangiopathy 
Macroangiopathy 
Insu/in treatment 
Fast-acting analog insulin 
Normal 
NPH 
Mix 
Glargine 
Pump 
Glargine vs. NPH + Mix +Normal 
Glargine + pump vs. NPH 
:j:Median (p10-p90). 
a Mean±S.D. 
NH 
59 (67%) 
56% 
37 ± 12 
14 (5-35) 
17% 
23.1 (19.5-28.1) 
8.1 (6.7-9.3) 
46% 
8% 
58% 
8% 
46% 
8% 
19% 
32% 
28% 
52% 
cantly lower than in patients without NH (8.1 vs. 9.3%, 
P = 0.007), cmTent smoking habit was already less frequent 
(OR= 0.36, P = 0.010). Non-smokers also had a lower HbA1c 
than smokers: 8.4% (6.3-10.3) versus 9.1% (8.1-9.7), 
P = 0.124. Lantus® was not a significant preventive factor of 
NH (OR=0.78, P=0.192). However, it produced less NH 
than treatment with NPH, mixed insulin and normal insulin 
(OR= 0.71, P = 0.076). 
4.6. Ejfect of NH on fasting glycaemia 
In the 2nd and 3rd nights, NH was associated with early 
moming hypoglycaemia (OR= 9.63, P<0.001) and inversely 
associated with early moming hyperglycaemia (OR= 0.70, 
P < 0.001). In patients who presented early moming hypergly-
caemia, 23% had NH, while 77% were euglycaemic or hyper-
glycaemic during the night. 
5. Evolution 6 to 9 months after CGMS 
Median HbA1c was 8.4% (6.8-9.9) before CGMS and low-
ered to 8.0% (7.2-10.4) 6-9 months after CGMS (P< 0.001). 
In the group of patients with NH (N = 59), median HbA1c was 
8.1% (6.7-9.3) before CGMS and 7.4% (7.0-9.3) after 
(P < 0.001). In the group without NH (N= 29), HbA1c lowered 
from 9.3% (7.1-10.3) to 8.9% (8.1-11.3) (P < 0.001). After 
CGMS, more patients did SMBG (from 20 to 43%) pmticularly 
at bedtime. Suspicion of clinical NH decreased from 60 to 14% 
during this time (P < 0.001). 
6. Discussion 
In this study, there was a high prevalence of noctumal 
hypoglycaemias (67%) that were often clinically unsuspected 
NoNH OR p 
29 (33%) 
55% 1.00 0.946 
39± 13 0.974 
11 (4-30) 0.432 
46% 0.36 0.010 
22.9 (19.4-30.2) 0.879 
9.3 (7.1-10.3) 0.007 
45% 1.02 0.919 
8% 1.01 0.962 
55% 1.03 0.827 
3% 1.27 0.379 
28% 1.28 0.102 
3% 1.27 0.379 
31% 0.78 0.192 
41% 0.87 0.397 
53% 0.71 0.076 
72% 0.75 0.067 
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(32%). Physicians often underestimate the prevalence of NH 
that CGMS was useful to detect. 
An episode of hypoglycaemia at bedtime (22-24 h) had a 
sensitivity of 37% to detect NH, while a single measure 
:::: 4 mmol/l at 03 h had a sensitivity of 43%, P = 0.57. There-
fore, a SMBG at bedtime is not less efficient than at 03 h to 
detect NH and is more convenient for the patient. In this line, 
Kaufmann et al. demonstrated, in a cohort of pediatric TlDM, 
that the level of glycaemia at bedtime (21 h) was correlated 
with the glycaemia measured by CGMS during the entire 
night [ 14]. Zavalkoff et al. studied correlations between four 
standard SMBG tests (breakfast, lunch, dinner and bedtime) 
and CGMS values [22]. They concluded that SMBG at bed-
time was correlated with the glycaemic level during the night. 
A treatrnent with Lantus® or with insulin pump was corre-
lated with fewer NH. New treatments with Lantus® are clini-
cally useful to reduce the risk of NH. A recently published 
study compared the frequency of hypoglycaemia in TlDM 
treated with Lantus® compared to patients treated with 
Ultralente® [23]. They concluded that the number of total and 
diurnal, but not noctumal hypoglycaemic events were lower on 
Lantus® than Ultralente®. In our study, patients who have pre-
sented NH had a lower HbA10, as expected; and were less often 
smokers. A Swedish study showed that TlDM who smoke had 
a poorer HbA10 values than non-smokers. They explained this 
observation by the fact that smokers had weaker degree of 
belief in health care professionals and are therefore less prone 
to follow instructions from the diabetes care team [24]. 
Other authors demonstrated that smoking decreases periph-
eral insulin sensitivity [25]. In our study, smokers had a higher 
HbA10 compared to non-smokers and had respectively less 
NH. But level ofHbA10 and current smoking were independent 
predictors of NH, then, we cannot purpose a correlation 
between absence of current smoking, low level of HbA10 and 
presence of NH altogether. 
Concerning Somogyi phenomenon, we observed that only 
23% of early morning hyperglycaemias are related to NH. In 
77% of the patients with early morning hyperglycaemia, 
patients were euglycaemic or hyperglycaemic during the night 
(P < 0.001). Therefore, in our study, we did not observe the 
Somogyi phenomenon, but quite the opposite. In a recently 
published study, Roi-Hansen et al. evaluated the probability 
of hypoglycaemic events in the night in TlDM, with the use 
of CGMS: this one was higher in case of low morning blood 
glucose [26]. Therefore, they also rejected the Somogyi phc-
nomenon. To our knowledge, there is no study that confirmed 
the existence of the Somogyi phenomenon with the use of 
CGMS [27]. This observation is important for the physicians 
because 77% of fasting hyperglycaemias are related to hyper or 
normoglycaemia during the night. The hypothetical risk of NH 
is low (23%). We observed that the clinical benefits of CGMS 
6-9 months later were a decrease ofHbA10 (from 8.4 to 8.0%) 
as described by Salardi et al. [ 4] and a significant reduction of 
clinical suspicion of NH (from 60 to 14%). This decrease of 
NH suspicion was important and may be partially explained by 
an increase of patients who performed SMBG at bedtime (from 
20 to 43%). Indeed, CGMS was useful as an educational tool 
for the patients who could see by this way their glycaemic pro-
file and the effects of food intake and daily activities [ 17, 18]. 
However CGMS cannot be used as a gold standard for the 
evaluation of the level of blood glucose. This device is very 
useful to access to the glycaemic profile of the patients and 
the trends to hypo or hyperglycaemia. This great option is 
now developed and used in combination with an insulin 
pump as in Gardian sensor system and Real Time sensor 
pump. The sensor informs the patient on the trends to high or 
low glucose levels. This instrument offers new perspectives for 
better anticipating glucose level variations. 
7. Limitations of the study 
This was a retrospective study and prospective studies of 
type 1 adult patients are needed to confirm our results. Sorne 
prospective studies have been done with a small cohmi of pre-
school children and adolescents [14-16], but not yet with 
adults. In our study, we evaluated only the evolution a short 
time after CGMS; therefore we have no evidence that meta-
bolic improvement of the diabetes still remains after more 
than 9 months. We included only TlDM and it would be inter-
esting to evaluate the CGMS in type 2 diabetic patients or 
gestational diabetes. Fmthermore, only patients who had an 
indication for CGMS were included, so these patients were 
not representative of the entire type 1 diabetic population. 
A limitation of our study is the accuracy and ability of 
CGMS to evaluate hypoglycaemias. Clarke and all observed 
that the CGMS missed the nadir ofhypoglycaemias and under-
estimated the duration of hypoglycaemias [19]. The CGMS 
was introduced in our center in 1999 and the first analyses 
were relatively of low quality. However, our study was per-
formed from 2001 to 2003, for this period we had acquired 
the expe1tise with relatively good quality for CGMS registra-
tion. 
8. Conclusion 
In our study, we showed that the prevalence of NH was 
high (67%) and that NH was often clinically unsuspected 
(32%). SMBG at bedtime were as efficient as at 03 h to predict 
NH, and more convenient for the patient. 
Somogyi phenomenon is rarely observed. Three quarters of 
fasting hyperglycaemias are related to hyper or normoglycae-
mia during the night rather then NH. If this observation is con-
firmed, we should modify our educational message for patients 
and health professionals. 
The CGMS is not an accurate device for the detection of 
NH, however the use of the trend curves can partially compen-
sate this defect. It is helpful to motivate patients to perform 
more SMBG and, for the medical team, to adjust treatment. 
This assertion was confirrned by a significant decrease of the 
HbA10 values and of the rate ofNH, 6-9 months after CGMS 
ex am. 
L. Gui/lad et al. / Diabetes & Metabolism 33 (2007) 360-365 365 
New perspectives for the CGMS include use of this device 
with an insulin pump to inform the patient about pathological 
glycaemic patterns. This is a great step towards the closed 
loop, the artificial pancreas. 
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